

Drugs and Devices Division

Drug Submission Status

Report for July 2019

Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Accord Healthcare Inc	ACH-Olmesartan HCTZ	Olmetec Plus	olmesartan medoxomil & hydrochlorothiazide	20 mg & 12.5 mg	tablet	02468948
Accord Healthcare Inc	ACH-Olmesartan HCTZ	Olmetec Plus	olmesartan medoxomil & hydrochlorothiazide	40 mg & 12.5 mg	tablet	02468956
Accord Healthcare Inc	ACH-Olmesartan HCTZ	Olmetec Plus	olmesartan medoxomil & hydrochlorothiazide	40 mg & 25 mg	tablet	02468964
Jamp Pharma Corporation	Jamp-Efavirenz	Sustiva	efavirenz	600 mg	tablet	02458233
Jamp Pharma Corporation	Jamp-Clindamycin	Dalacin C	clindamycin HCl	150 mg	capsule	02483734

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp-Clindamycin	Dalacin C	clindamycin HCl	300 mg	capsule	02483742
Marcan Pharmaceuticals Inc.	Mar-Trospium	Trosec	trospium chloride	20 mg	tablet	02488353